Taysha Gene Therapies Inc... (TSHA)
NASDAQ: TSHA
· Real-Time Price · USD
2.54
0.00 (0.00%)
At close: Jun 16, 2025, 3:59 PM
2.56
0.79%
After-hours: Jun 16, 2025, 07:53 PM EDT
0.00% (1D)
| Bid | 2.48 |
| Market Cap | 664.29M |
| Revenue (ttm) | 7.22M |
| Net Income (ttm) | -86.77M |
| EPS (ttm) | -0.32 |
| PE Ratio (ttm) | -7.94 |
| Forward PE | -6.7 |
| Analyst | Buy |
| Ask | 2.7 |
| Volume | 3,079,384 |
| Avg. Volume (20D) | 3,628,914 |
| Open | 2.57 |
| Previous Close | 2.54 |
| Day's Range | 2.48 - 2.60 |
| 52-Week Range | 1.05 - 4.07 |
| Beta | 1.02 |
About TSHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TSHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TSHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+12.7%
Taysha Gene Therapies shares are trading higher af...
Unlock content with
Pro Subscription
2 weeks ago
-6.51%
Taysha Gene Therapies shares are trading higher. The company announced a proposed public offering of common stock.
2 weeks ago · seekingalpha.com
Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP AmendmentsTaysha Gene Therapies, Inc. achieved positive updated data from Part A of the phase 1/2 REVEAL study using TSHA-102 to treat patients with Rett Syndrome. Alignment gained with FDA on IND amendments to...
1 month ago · seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call TranscriptTaysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Hayleigh Collins - Senior Director, Corporate Communications and Investor Relat...
